In a study, elevated FGF23 was associated with increased risks of major adverse cardiovascular events and mortality in type 2 diabetes patients with normal or mildly impaired kidney function.
If confirmed, findings from 2 new studies would have important clinical implications for phosphate intake in the general population.
In a 2-day dietary intervention study, very-low-phosphate and low-phosphate diets decreased fibroblast growth factor 23 levels to a similar degree in patients on hemodialysis, but the very-low-phosphate diets results in greater lowering of phosphorus levels.
Prescriptions of drugs to treat chronic kidney disease-mineral bone disorders varies widely by country, but it is generally low, a study found.
The phosphate binder ferric citrate coordination complex may mitigate anemia, elevated phosphorus, and FGF23 in patients with advanced CKD, new research suggests.
In a study, the risks for cardiovascular events and all-cause mortality were only a nonsignificant 4% lower for sevelamer vs calcium acetate recipients older than 65 years initiating hemodialysis.
Hemodialysis patients who stayed on the phosphate binder sucroferric oxyhydroxide for 2 years had fewer hospitalizations those who switched to another binder for 2 years.
According to preliminary research, phosphate binders may bind to helpful substances such as vitamin K, but also to harmful ones, such as lipopolysaccharides and advanced glycation end products.
In a small study, vitamin K antagonist use and liver dysfunction emerged as the most important factors in the development of calciphylaxis.
Researchers estimate that half of calcium channel blockers, for example, contain phosphorus as an excipient.